Financial Contrast: DarioHealth (NASDAQ:DRIO) versus PROCEPT BioRobotics (NASDAQ:PRCT)

DarioHealth (NASDAQ:DRIO) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Analyst Ratings

This is a summary of current ratings and recommmendations for DarioHealth and PROCEPT BioRobotics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DarioHealth	0	1	1	0	2.50
PROCEPT BioRobotics	0	1	6	0	2.86

DarioHealth presently has a consensus price target of $2.50, suggesting a potential upside of 303.23%. PROCEPT BioRobotics has a consensus price target of $97.86, suggesting a potential upside of 34.98%. Given DarioHealth’s higher possible upside, equities analysts plainly believe DarioHealth is more favorable than PROCEPT BioRobotics.

Earnings & Valuation

This table compares DarioHealth and PROCEPT BioRobotics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DarioHealth	$23.05 million	0.92	-$59.43 million	($0.94)	-0.66
PROCEPT BioRobotics	$136.19 million	27.78	-$105.90 million	($1.95)	-37.18

DarioHealth has higher earnings, but lower revenue than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares DarioHealth and PROCEPT BioRobotics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DarioHealth	-205.62%	-72.16%	-40.74%
PROCEPT BioRobotics	-50.07%	-38.57%	-26.06%

Risk & Volatility

DarioHealth has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500.

Institutional and Insider Ownership

33.4% of DarioHealth shares are owned by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 16.5% of DarioHealth shares are owned by company insiders. Comparatively, 17.4% of PROCEPT BioRobotics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

PROCEPT BioRobotics beats DarioHealth on 9 of the 14 factors compared between the two stocks.

About DarioHealth

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.